Substituted tricyclic benzimidazoles as kinase inhibitors
US9745299B2 · kind B2 · utility
1Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 2013 |
| Grant date | Aug 29, 2017 |
| Priority date | — |
| Expiry date | Nov 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.